Investors

Feb 8, 2012

TSX Symbol: RVX

CALGARY, Feb. 8, 2012 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce that Donald McCaffrey, President & Chief Executive Officer of Resverlogix will be presenting at The 14^th Annual BIO CEO & Investor Conference on February 13, 2012 at 1:30 PM (EST) at the Waldorf Astoria, New York City.

The presentation will be available via live Webcast and subsequent replay at: http://www.veracast.com/webcasts/bio/ceoinvestor2012/01111295.cfm.

Resverlogix will also post the Webcast link to the Events section of their website at: http://www.resverlogix.com/media/events. The archived replay will be available for a period of 45 days following the live event.

About Resverlogix

Resverlogix is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. These vital therapies are focused on addressing the burden of Atherosclerosis and many other important diseases including Acute Coronary Syndrome, Alzheimer's disease, Peripheral Artery Disease and Autoimmune diseases. The NexVas Plaque Regression program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I production and thereby raise high density lipoprotein (HDL) for the treatment of Atherosclerosis. Lead drug RVX-208 is currently in two Phase 2b Clinical Trials led by the Cleveland Clinic. Resverlogix's common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risks including but not limited to those assumptions and risk factors discussed in the Company's Annual Information Form and MD&A for the interim period ended October 31, 2011 which are incorporated herein by reference and other documents we file from time to time with securities authorities, which are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information please contact: